Display options
Cite
Trobaugh-Lotrario A, Katzenstein HM, Ranganathan S, et al. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. J Clin Oncol. 2021;JCO2100803doi: 10.1200/JCO.21.00803.
Trobaugh-Lotrario, A., Katzenstein, H. M., Ranganathan, S., Lopez-Terrada, D., Krailo, M. D., Piao, J., Chung, N., Randazzo, J., Malogolowkin, M. H., Furman, W. L., McCarville, E. B., Towbin, A. J., Tiao, G. M., Dunn, S. P., Langham, M. R., McGahren, E. D., Feusner, J., Rodriguez-Galindo, C., Meyers, R. L., O'Neill, A. F., & Finegold, M. J. (2021). Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2100803. https://doi.org/10.1200/JCO.21.00803
Trobaugh-Lotrario, Angela, et al. "Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2021): JCO2100803. doi: https://doi.org/10.1200/JCO.21.00803
Trobaugh-Lotrario A, Katzenstein HM, Ranganathan S, Lopez-Terrada D, Krailo MD, Piao J, Chung N, Randazzo J, Malogolowkin MH, Furman WL, McCarville EB, Towbin AJ, Tiao GM, Dunn SP, Langham MR, McGahren ED, Feusner J, Rodriguez-Galindo C, Meyers RL, O'Neill AF, Finegold MJ. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee. J Clin Oncol. 2021 Dec 07;JCO2100803. doi: 10.1200/JCO.21.00803. Epub 2021 Dec 07. PMID: 34874751.
Copy Download .nbib Format: NLM
Share it on

J Clin Oncol. 2021 Dec 07;JCO2100803. doi: 10.1200/JCO.21.00803. Epub 2021 Dec 07.

Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Angela Trobaugh-Lotrario, Howard M Katzenstein, Sarangarajan Ranganathan, Dolores Lopez-Terrada, Mark D Krailo, Jin Piao, Nadia Chung, Jessica Randazzo, Marcio H Malogolowkin, Wayne L Furman, Elizabeth B McCarville, Alexander J Towbin, Greg M Tiao, Stephen P Dunn, Max R Langham, Eugene D McGahren, James Feusner, Carlos Rodriguez-Galindo, Rebecka L Meyers, Allison F O'Neill, Milton J Finegold

Affiliations

  1. Sacred Heart Children's Hospital, Spokane, WA.
  2. Nemours Children's Specialty Care and Wolfson Children's Hospital, Jacksonville, FL.
  3. Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  4. Baylor College of Medicine, Houston, TX.
  5. University of Southern California Keck School of Medicine, Los Angeles, CA.
  6. Children's Oncology Group, Monrovia, CA.
  7. University of California at Davis Comprehensive Cancer Center, Sacramento, CA.
  8. University of Tennessee Health Science Center and St Jude Children's Research Hospital, Memphis, TN.
  9. AI duPont Hospital for Children and Thomas Jefferson University, Philadelphia, PA.
  10. University of Virginia Children's Hospital and University of Virginia, Charlottesville, VA.
  11. Benioff Children's Hospital, Oakland, CA.
  12. Primary Children's Medical Center, Salt Lake City, UT.
  13. Dana-Farber Cancer Institute, and Boston Children's Hospital, Boston, MA.

PMID: 34874751 DOI: 10.1200/JCO.21.00803

Abstract

PURPOSE: Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Children's Oncology Group (COG) study AHEP0731 underwent institutional and central pathologic review for identification of SCU histology.

PATIENTS AND METHODS: Patients with SCU histology identified at the local treating institution who had otherwise low-risk tumors were upstaged to the intermediate-risk treatment stratum, whereas those only identified by retrospective central review were treated per the local institution as low-risk. Patients with otherwise intermediate- or high-risk tumors remained in that treatment stratum, respectively. Central review was to be performed for all tissue samples obtained at any time point. Treatment was per local review, whereas analysis of outcome was based on central review.

RESULTS: Thirty-five patients had some elements (1%-25%) of SCU identified on central review of diagnostic specimens. All but two patient tissue sample retained nuclear INI1 expression. The presence of SCU histology did not correlate with age, alpha-fetoprotein level at diagnosis, or sex. The presence of SCU did not affect event-free survival (EFS). EFS at 5 years for patients with low-risk, intermediate-risk, and high-risk with SCU HB was 86% (95% CI, 33 to 98), 81% (95% CI, 57 to 92), and 29% (95% CI, 4 to 61), respectively, compared with EFS at 5 years for patients without SCU enrolled with low-risk, intermediate-risk, and high-risk of 87% (95% CI, 72 to 95), 88% (95% CI, 79 to 94), and 55% (95% CI, 32 to 74;

CONCLUSION: The presence of SCU histology in HB does not appear to adversely affect outcome. Future studies should be able to treat patients with SCU HB according to risk stratification without regard to the presence of SCU histology.

Publication Types

Grant support